Rigel Pharmaceuticals (RIGL) Corporate presentation summary

Transformational growth strategy

• Focused on growing the commercial business, advancing the development pipeline, maintaining financial discipline, and pursuing in-licensing/business development opportunities.

• Expanded from one commercial product in 2020 to three by 2025, with a robust pipeline including R289 for lower-risk MDS.

• Achieved profitability since Q3 2024, with a significant increase in cash position.

• Targeting further growth through potential M&A and in-licensing in the 2030s.

Commercial performance and revenue growth

• Net product sales grew at a ~35% CAGR from 2022 to 2026, reaching a projected $232M in 2025 and $260M in 2026.

• Q4 2025 net portfolio sales increased 41% year-over-year, with TAVALISSE, GAVRETO, and REZLIDHIA all showing strong growth.

• TAVALISSE led with $45.6M in Q4 2025 sales (47% growth), GAVRETO at $10.2M (27% growth), and REZLIDHIA at $9.6M (29% growth).

• Expanded commercial access globally, with TAVALISSE available in key international markets and new regulatory approvals in Mexico.

Product portfolio and market opportunities

• TAVALISSE is indicated for chronic immune thrombocytopenia (cITP) and has demonstrated efficacy across multiple lines of therapy.

• REZLIDHIA targets relapsed/refractory AML with IDH1 mutation, addressing a significant unmet need and showing durable responses in clinical trials.

• GAVRETO is approved for RET fusion-positive NSCLC and thyroid cancer, offering a differentiated, once-daily oral therapy with strong efficacy and safety.